Context Therapeutics (NASDAQ:CNTX) Releases Earnings Results, Misses Estimates By $0.04 EPS

Context Therapeutics (NASDAQ:CNTX) announced its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.04), FiscalAI reports.

Context Therapeutics Stock Performance

CNTX traded up $0.14 during trading on Monday, hitting $3.02. The stock had a trading volume of 480,492 shares, compared to its average volume of 1,695,931. The firm has a market capitalization of $277.48 million, a P/E ratio of -12.58 and a beta of 1.97. The company’s 50-day moving average price is $2.35 and its 200 day moving average price is $1.57. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.62.

Analyst Ratings Changes

A number of analysts recently issued reports on CNTX shares. JonesTrading started coverage on Context Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Lifesci Capital raised Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Wall Street Zen raised shares of Context Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Context Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CNTX. Virtu Financial LLC purchased a new stake in shares of Context Therapeutics in the fourth quarter valued at about $43,000. XTX Topco Ltd grew its position in shares of Context Therapeutics by 858.8% in the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Context Therapeutics during the 4th quarter valued at about $68,000. Millennium Management LLC purchased a new position in Context Therapeutics during the fourth quarter worth approximately $3,824,000. Finally, Marshall Wace LLP increased its stake in Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after acquiring an additional 2,557,448 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.